New analyses found differences in functional outcomes over 2 years among patients aged 8 to 12 years treated with ...
Dompé has enrolled the first patient in a phase 2 trial testing whether intranasal nerve growth factor (NGF) can safely be given to young children with spastic cerebral palsy (CP ...
How clinicians can turn everyday observations into publishable research: spotting the gap, choosing the right paper type, and ...
The professor of neurology at the University of Michigan Medical School discussed the themes that defined SLEEP 2026, and what they signal for clinical practice heading into 2027. [WATCH TIME: 5 ...
Welcome to NeurologyLive® 's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive 's widespread coverage in ...
The Galassia trial will evaluate the safety and tolerability of intranasal cenegermin in about 60 children with spastic cerebral palsy across Italy. The chief medical officer at Mandos Health ...
The FDA was busy in September 2026, issuing a number of decisions on potential new therapies, including approvals, clearances ...
Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA. The professor of ...
Brain insulin resistance serves as the current thematic focus, reinforcing emerging metabolic-neurologic intersections ...
Congressional passage would extend ACT for ALS programs and associated research grants through FY2031, sustaining federal ...
Former NASCAR driver Darrell Waltrip recently announced a diagnosis of frontotemporal dementia (FTD). Waltrip, a 3-time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results